FGF19: A Literature Course on What the Published Studies Report

This page is a structured reading guide to the published FGF19 literature. It is organised as six modules, each ending with an explicit statement of where the evidence stops. Nothing here is a protocol, a recommendation, or a description of human use. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, medication, or research participation.

Module 1: What FGF19 Is and How It Has Been Studied

Definition and class

FGF19 belongs to the endocrine branch of the fibroblast growth factor family. Unlike classical FGFs, which act locally and bind heparan sulphate tightly, the endocrine FGFs circulate and require a Klotho co-receptor to engage their receptor tyrosine kinase. In FGF19's case the literature describes signalling through fibroblast growth factor receptor 4 (FGFR4) together with β-Klotho (KLB), a receptor–co-receptor pairing examined directly in a hepatocellular carcinoma study of FGF19/FGFR4/KLB signalling (PMID 41654439). A dedicated review of FGF19–FGFR4 signalling in hepatocellular carcinoma set out the same axis as the central framework for interpreting FGF19 biology in liver tissue (PMID 31167419).

An important framing point: although FGF19 is often filed alongside "peptides" in general-interest writing, the published work treats it as a full-length protein hormone produced by cells, not as a short chemically synthesised peptide sequence. Studies typically use recombinant protein, genetic overexpression, knockdown, or antibodies and inhibitors that interrupt the pathway.

Origin and forms

FGF19 in humans has a rodent counterpart, FGF15, and the two are frequently written together as FGF15/FGF19 because mouse experiments read onto human biology through that orthologue. An autophagy study described a feeding-activated FGF15/FGF19–NR0B2/SHP–TFEB pathway acting on gut lipophagy, using the paired nomenclature explicitly (PMID 35913833). The hormone is classically discussed as an ileal, bile-acid-responsive signal that travels to the liver, and the feeding-linked work above is consistent with that postprandial framing.

How it has been studied

Across the verified papers, four study formats recur:

• Cell culture and organoid work — chondrocytes, hepatocellular carcinoma lines, colorectal cancer cells, endometrial cancer cells and fibroblasts.
• Genetically or chemically challenged mice — diet-induced obesity, bleomycin-induced lung injury, metastasis models.
• Human tissue comparisons — for example, researchers reported that FGF19 was downregulated in idiopathic pulmonary fibrosis tissue relative to controls (PMID 35549849).
• Pathway-interference pharmacology — such as a gastric cancer study in which the multikinase inhibitor lenvatinib was reported to suppress FGF19–FGFR4 signalling (PMID 39948303).

Limits of the evidence: Module 1

The verified literature set defines FGF19 biologically but does not establish it as an administered therapeutic agent in people. No paper in this set describes a controlled human trial of FGF19 administration, a formulation, or a route of delivery intended for clinical use.

Module 2: Mechanism as Described in the Literature

The receptor complex

The recurring mechanistic backbone is FGF19 → FGFR4 (+ β-Klotho) → downstream kinase cascades. The hepatocellular carcinoma review framed FGFR4 as the dominant receptor for FGF19 in liver and organised the field's findings around that interaction (PMID 31167419), and the ferroptosis paper examined FGF19/FGFR4/KLB signalling as a unit in hepatocellular carcinoma (PMID 41654439).

AMPKα–p38/MAPK and mitochondria

Two independent papers converge on a mitochondrial arm. In chondrocytes, researchers reported that FGF19 increased mitochondrial biogenesis and fusion via the AMPKα–p38/MAPK pathway (PMID 36915160). In bleomycin-induced pulmonary fibrosis, a separate group reported that FGF19 influenced mitochondrial dynamics and macrophage polarisation through an FGFR4/AMPKα–p38/MAPK axis (PMID 40550190). The shared kinase route across two different tissues is one of the more reproducible mechanistic threads in this set.

Transcriptional and autophagy arms

The colorectal cancer literature describes a transcription-factor arm: the study reported that FGF19-mediated ELF4 overexpression promoted colorectal cancer metastasis by transactivating FGFR4 and SRC (PMID 36923538). In the gut, a separate mechanism was described in which FGF15/FGF19 acted through NR0B2/SHP and the autophagy–lysosome regulator TFEB to activate lipophagy in a feeding-dependent, and the authors' word, paradoxical manner (PMID 35913833).

A central nervous system arm

Not all FGF19 signalling described in the literature is peripheral. A mouse study reported that Rsk4 mediated brain FGF19 signalling to constrain diet-induced obesity (PMID 42301138), placing part of the metabolic phenotype upstream of the liver and inside the central nervous system.

Stromal and immune arms

FGF19 signalling has also been described as acting on non-tumour cells within a tissue. One study reported that FGF19 induced an inflammatory cancer-associated fibroblast phenotype that promoted neutrophil extracellular trap formation in colorectal cancer liver metastasis (PMID 37345586), and an endometrial cancer study described a lipid-driven OLR1/FOXM1/FGF19 axis operating as epithelial–fibroblast crosstalk in a positive feedback loop (PMID 41270216).

Limits of the evidence: Module 2

These mechanisms were mapped in cells and animals, often with overexpression or knockdown tools that push the system far outside physiological range. Pathways identified in a chondrocyte or a tumour line do not automatically describe what circulating FGF19 does in an intact human, and none of these papers resolved which arm dominates when all are active at once.

Module 3: Reported Outcomes by Study

The table below summarises the model, the endpoint and the reported direction of effect for each verified paper. No paper in this set supports a human benefit claim, and doses are not listed because the verified abstract-level records do not supply dosing that can be stated accurately.

Reading the table without over-reading it

Two opposite-looking clusters sit side by side. In metabolic, skeletal and fibrotic models, FGF19 signalling was reported as constraining an unwanted process — obesity, bone loss, lung fibrosis. In oncology models, the same signalling was reported as enabling tumour progression. Both clusters are real published findings, and neither cancels the other; they describe different tissues, different disease contexts and different experimental manipulations.

Limits of the evidence: Module 3

Every outcome above is preclinical. Endpoints such as mitochondrial fusion, macrophage polarisation or fibrosis scores in mice are surrogate measures, not clinical outcomes. None of the studies reported symptom scores, quality-of-life measures, or survival in humans receiving FGF19, and no study in this set was a randomised controlled trial.

Module 4: Fgf19 Side Effects: What Studies Report

There is no human safety database in the verified literature — no trial reporting injection-site reactions, laboratory abnormalities or discontinuation rates. What the literature does report, repeatedly, is a biological risk signal tied to the FGF19–FGFR4 axis itself.

The oncology signal

The most consistent published concern is the association between FGF19–FGFR4 signalling and cancer. A review of hepatocellular carcinoma framed FGF19–FGFR4 signalling as a pathway of interest precisely because of its role in liver tumour biology (PMID 31167419), and a separate hepatocellular carcinoma study reported that FGF19/FGFR4/KLB signalling participated in ferroptosis regulation, a death pathway tumour cells can exploit to survive (PMID 41654439).

Outside the liver, the study in colorectal cancer reported that FGF19-mediated ELF4 overexpression promoted metastasis through FGFR4 and SRC (PMID 36923538), while another reported that FGF19 drove inflammatory cancer-associated fibroblasts and neutrophil extracellular trap formation in colorectal cancer liver metastasis (PMID 37345586). In gastric cancer, researchers reported that suppressing — not increasing — FGF19–FGFR4 signalling with lenvatinib enhanced the antitumour immune response (PMID 39948303). In endometrial cancer, a lipid-driven OLR1/FOXM1/FGF19 axis was reported to promote progesterone resistance (PMID 41270216).

Taken together, five independent tumour-type papers in this set describe FGF19 pathway activity as pro-tumour or therapy-resistance-associated. That is a hazard characterisation drawn from disease biology rather than an adverse-event table, but it is the dominant safety-relevant theme in the published record.

Limits of the evidence: Module 4

These are tumour-model observations, not documented adverse events in people given FGF19. The absence of reported human adverse events in this set reflects the absence of human administration studies, not a demonstration of safety. No paper here quantified a threshold of exposure, a duration, or a population in which harm was or was not observed.

Module 5: Pharmacokinetics, Where Data Exist

Pharmacokinetics is where this literature is thinnest. None of the verified papers reported human absorption, distribution, metabolism or elimination values for FGF19 — no half-life, no bioavailability figure, no clearance estimate, no dose-proportionality analysis.

What can be said from the verified set is qualitative and structural:

• Endocrine mode of action. The requirement for β-Klotho alongside FGFR4, examined in hepatocellular carcinoma (PMID 41654439), implies that tissue responsiveness depends on co-receptor expression rather than on circulating concentration alone.
• Feeding-linked dynamics. A study described FGF15/FGF19 signalling to NR0B2/SHP and TFEB as activated by feeding (PMID 35913833), consistent with a postprandial rather than constant signal.
• Central access. That brain FGF19 signalling through Rsk4 constrained diet-induced obesity in mice (PMID 42301138) indicates a central compartment is relevant to the phenotype, though the study did not supply human pharmacokinetic parameters.

Limits of the evidence: Module 5

No pharmacokinetic profile for FGF19 can be stated from this evidence base. Any number circulating outside the peer-reviewed record — a half-life, a dose, a frequency — is not supported by the papers summarised here and is omitted rather than approximated.

Module 6: Regulatory Status, Stated Factually

Approved products

The verified literature set contains no approved FGF19 drug product. The papers describe FGF19 as an endogenous signalling protein studied in laboratories, and where a marketed medicine appears it appears as an inhibitor of the pathway: researchers reported that lenvatinib, a multikinase inhibitor, suppressed FGF19–FGFR4 signalling in gastric cancer (PMID 39948303). The direction of therapeutic interest in oncology has been toward blocking this axis, a framing set out in the hepatocellular carcinoma review (PMID 31167419).

Research-use-only material

Recombinant FGF19 protein used in laboratory work is supplied as research-use-only (RUO) material. RUO labelling in the United States signifies that a substance is intended for laboratory investigation and is not an approved drug, is not manufactured to pharmaceutical standards for human administration, and carries no clinical labelling, indication or safety review.

Compounding

Under US law, compounding pharmacies operating under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act may compound only from bulk drug substances that meet defined statutory criteria — for example, substances that are components of approved drugs, that appear in an applicable monograph, or that FDA has placed on the relevant bulk substances list. A protein with no approved product and no such listing does not meet those criteria. FDA has separately acted against the compounding of various peptide substances that lack this status. This section states regulatory facts for general education and is not legal advice; questions about a specific substance, jurisdiction or practice should be directed to qualified counsel or the relevant regulator.

Limits of the evidence: Module 6

Regulatory classification changes over time and varies by country. The statements above describe the general framework and the content of the verified literature; they are not a substitute for checking a current regulatory database.

Closing: What the Studies Did Not Test

Reading the twelve verified papers together, the gaps are as instructive as the findings:

1. No human administration. No study in this set gave FGF19 to people and measured outcomes.
2. No dose–response in humans. The set supports no statement about an amount, a schedule or a duration.
3. No long-term safety follow-up. Given that five papers describe FGF19 pathway activity as pro-tumour in colorectal, gastric, hepatic and endometrial models (PMID 36923538, PMID 41270216), the absence of longitudinal safety data is a conspicuous gap.
4. No head-to-head comparisons. No study compared FGF19 with an established treatment for obesity, bone loss, osteoarthritis or pulmonary fibrosis.
5. No resolution of the paradox. The protective findings in fibrosis and bone models (PMID 35549849, PMID 34906775) and the pro-tumour findings in oncology models have not been reconciled in a single experimental system.
6. No healthy-population data. Every model involved a disease state, a genetic manipulation or a chemical challenge.

The honest summary of FGF19 at this stage is that it is a well-characterised endogenous signalling protein with a mechanistically rich preclinical literature and an unresolved risk profile — not a studied human intervention.

References

• FGF19-mediated ELF4 overexpression promotes colorectal cancer metastasis through transactivating FGFR4 and SRC (Theranostics, 2023)
• FGF19-Induced Inflammatory CAF Promoted Neutrophil Extracellular Trap Formation in the Liver Metastasis of Colorectal Cancer (Advanced Science, 2023)
• Rsk4 Mediates Brain FGF19 Signaling to Constrain Diet-Induced Obesity in Mice (Diabetes, 2026)
• FGF19 Is Downregulated in Idiopathic Pulmonary Fibrosis and Inhibits Lung Fibrosis in Mice (American Journal of Respiratory Cell and Molecular Biology, 2022)
• Lenvatinib suppress FGF19-FGFR4 signaling to enhance antitumor immune response in gastric cancer (Gastric Cancer, 2025)
• FGF19/FGFR4/KLB signaling participate in the ferroptosis regulation of hepatocellular carcinoma (Arab Journal of Gastroenterology, 2026)
• Lipid-Driven OLR1/FOXM1/FGF19 Axis Orchestrates Crosstalk in an Epithelial-Fibroblast Positive Feedback Promoting Progesterone Resistance in Endometrial Cancer (Advanced Science, 2026)
• Role of FGF19 in regulating mitochondrial dynamics and macrophage polarization through FGFR4/AMPKα-p38/MAPK Axis in bleomycin-induced pulmonary fibrosis (Cytokine, 2025)
• FGF19 protects against obesity-induced bone loss by promoting osteogenic differentiation (Biomedicine & Pharmacotherapy, 2022)
• FGF19 increases mitochondrial biogenesis and fusion in chondrocytes via the AMPKα-p38/MAPK pathway (Cell Communication and Signaling, 2023)
• FGF19-FGFR4 Signaling in Hepatocellular Carcinoma (Cells, 2019)
• Paradoxical feeding activation of gut lipophagy by FGF15/FGF19-NR0B2/SHP-TFEB (Autophagy, 2023)